^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Litfulo (ritlecitinib)

    i
    Other names: PF-06651600, PF-6651600, PF 6651600, PF 06651600, PF6651600
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    JAK3 inhibitor, TEC inhibitor
    Related drugs:
    Associations

    News

    Trials
    11d
    B7981119: A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=240, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    14d
    A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice. (clinicaltrials.gov)
    P=N/A, N=3000, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Mar 2030 | Trial primary completion date: Sep 2030 --> Mar 2030
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Litfulo (ritlecitinib)
    18d
    Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission (clinicaltrials.gov)
    P2, N=40, Recruiting, Massachusetts General Hospital | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Litfulo (ritlecitinib)
    21d
    A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Pfizer
    New P2 trial
    |
    Litfulo (ritlecitinib)
    23d
    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (clinicaltrials.gov)
    P2, N=200, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    25d
    Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Pfizer
    New trial • Real-world evidence
    |
    Litfulo (ritlecitinib)
    1m
    Designing new hit series of JAK3 inhibitors using generative AI, reinforcement learning, and molecular dynamics. (PubMed, Comput Biol Med)
    In a benchmark for ritlecitinib, we found that scaffolds NS_1813 and NS_2063 showed better binding affinities, with 20 compounds meeting our selection criteria...From these, six lead compounds were chosen for detailed molecular dynamics and docking pose analyses to assess their conformational stability and binding interactions within the JAK3 active site. These compounds are promising candidates for further development, including chemical synthesis, followed by in vitro and in vivo testing to evaluate their potential as JAK3-targeting therapeutic agents.
    Journal
    |
    JAK3 (Janus Kinase 3)
    |
    Litfulo (ritlecitinib)
    1m
    A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Pfizer
    New P2 trial
    |
    Litfulo (ritlecitinib)
    2ms
    Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. (PubMed, Dermatol Ther (Heidelb))
    NCT06873945. Video Abstract (MP4 303790 kb).
    Clinical • P3 data • Journal
    |
    JAK3 (Janus Kinase 3)
    |
    Litfulo (ritlecitinib)
    2ms
    B7981028: A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. (clinicaltrials.gov)
    P3, N=140, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Litfulo (ritlecitinib)
    2ms
    Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) (clinicaltrials.gov)
    P2, N=78, Active, not recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Litfulo (ritlecitinib)
    2ms
    Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy (clinicaltrials.gov)
    P2, N=30, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: May 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Litfulo (ritlecitinib)